2つのフェーズ3試験解析からみた乾癬性関節炎患者におけるイキセキズマブの体軸症状への効果: SPIRIT-P1 と SPIRIT-P2
Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005 doi: 10.1177/1759720X231189005
Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.